Discover emerging blood biomarkers that could improve risk assessment, clinical validation, and outcome prediction in pulmonary arterial hypertension. Leading experts will share new insights into proteomics, NOTCH3-ECD, oxysterol and bile acid synthesis, endostatin, and vascular dysfunction.
